Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Untch

Showing results (121-130 of 169) with videos related to

Pageof 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patientsN Harbeck, M Schmitt, C Meisner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Nuklearmedizin. Nuclear Medicine|February 24, 2004
[Sentinel node biopsy in breast cancer]T Kühn, A Bembenek, H Büchels, et al.
Der Pathologe|June 11, 2004
[Sentinel node biopsy in breast carcinoma. Interdisciplinary agreement consensus of the German Society for Serology for quality controlled application in routine clinical testing]T Kühn, A Bembenek, H Büchels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN studyJ Furlanetto, W Eiermann, F Marmé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2010
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trialG von Minckwitz, H Eidtmann, S Loibl, et al.
British Journal of Cancer|September 14, 2006
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trialA Chan, M Martin, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trialV Möbus, C Jackisch, H J Lück, et al.
Pageof 17

Showing results (121-130 of 169) with videos related to

Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patientsN Harbeck, M Schmitt, C Meisner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Nuklearmedizin. Nuclear Medicine|February 24, 2004
[Sentinel node biopsy in breast cancer]T Kühn, A Bembenek, H Büchels, et al.
Der Pathologe|June 11, 2004
[Sentinel node biopsy in breast carcinoma. Interdisciplinary agreement consensus of the German Society for Serology for quality controlled application in routine clinical testing]T Kühn, A Bembenek, H Büchels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN studyJ Furlanetto, W Eiermann, F Marmé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2010
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trialG von Minckwitz, H Eidtmann, S Loibl, et al.
British Journal of Cancer|September 14, 2006
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trialA Chan, M Martin, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trialV Möbus, C Jackisch, H J Lück, et al.
Pageof 17